Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

The FDA on Friday approved Acadia Pharmaceuticals’ treatment for Rett syndrome, a rare neurodevelopmental disorder, which will be sold under the brand name Daybue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

Sign up to read this article for free.

J&J takes 340B fight with federal government to court

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

Associate Editor

Executive Editor

Sign up to read this article for free.

Updated: Acadia wins first FDA approval for Rett syndrome drug